secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001326190-23-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q3 net loss $0.39/sh; cash $140.8M; obesity trial readout Q4 2023
---------------------------------------------------------------------------

- Net loss $20.7M ($0.39/sh) vs $23.5M ($0.48) in Q3 2022.
- Cash, equivalents & short-term investments $140.8M as of Sep 30, 2023.
- Top-line 48-week MOMENTUM Phase 2 obesity trial data expected Q4 2023; 391 subjects randomized.
- HepTcell Phase 2 CHB top-line results anticipated Q1 2024; ~80 subjects enrolled.
- Pemvidutide granted Fast Track for NASH; IMPACT Phase 2b enrollment ongoing; results Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/0001326190-23-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/alt-20231107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-23-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer